Abstract
Background: Hypertension and renal injury are common complications of type 2 diabetes mellitus (T2DM). Hyperglycemia stimulates renal proximal tubular angiotensinogen (AGT) expression via elevated oxidative stress contributing to the development of high blood pressure and diabetic nephropathy. The sodium glucose cotransporter 2 (SGLT2) in proximal tubules is responsible for the majority of glucose reabsorption by renal tubules. We tested the hypothesis that SGLT2 inhibition with canagliflozin (CANA) prevents intrarenal AGT augmentation and ameliorates kidney injury and hypertension in T2DM. Methods: We induced T2DM in New Zealand obese mice with a high fat diet (DM, 30% fat) with control mice receiving regular fat diet (ND, 4% fat). When DM mice exhibited > 350 mg/dL blood glucose levels, both DM- and ND-fed mice were treated with 10 mg/kg/day CANA or vehicle by oral gavage for 6 weeks. We evaluated intrarenal AGT, blood pressure, and the development of kidney injury. Results: Systolic blood pressure in DM mice (133.9 ± 2.0 mm Hg) was normalized by CANA (113.9 ± 4.0 mm Hg). CANA treatment ameliorated hyperglycemia-associated augmentation of renal AGT mRNA (148 ± 21 copies/ng RNA in DM, and 90 ± 16 copies/ng RNA in DM + CANA) and protein levels as well as elevation of urinary 8-isoprostane levels. Tubular fibrosis in DM mice (3.4 ± 0.9-fold, fibrotic score, ratio to ND) was suppressed by CANA (0.9 ± 0.3-fold). Furthermore, CANA attenuated DM associated increased macrophage infiltration and cell proliferation in kidneys of DM mice. Conclusions: CANA prevents intrarenal AGT upregulation and oxidative stress and which may mitigate high blood pressure, renal tubular fibrosis, and renal inflammation in T2DM.
References
1.
Elmarakby AA, Abdelsayed R, Yao Liu J, Mozaffari MS. Inflammatory cytokines as predictive markers for early detection and progression of diabetic nephropathy.
EPMA J
. 2010 Mar; 1(1): 117–29.2.
Varga ZV, Giricz Z, Liaudet L, Haskó G, Ferdinandy P, Pacher P. Interplay of oxidative, nitrosative/nitrative stress, inflammation, cell death and autophagy in diabetic cardiomyopathy.
Biochim Biophys Acta
. 2015 Feb; 1852(2): 232–42.3.
Navar LG, Prieto MC, Satou R, Kobori H. Intrarenal angiotensin II and its contribution to the genesis of chronic hypertension.
Curr Opin Pharmacol
. 2011 Apr; 11(2): 180–6.4.
Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease.
Pharmacol Rev
. 2007 Sep; 59(3): 251–87.5.
Miyata K, Ohashi N, Suzaki Y, Katsurada A, Kobori H. Sequential activation of the reactive oxygen species/angiotensinogen/renin-angiotensin system axis in renal injury of type 2 diabetic rats.
Clin Exp Pharmacol Physiol
. 2008 Aug; 35(8): 922–7.6.
Park S, Bivona BJ, Kobori H, Seth DM, Chappell MC, Lazartigues E, et al. Major role for ACE-independent intrarenal ANG II formation in type II diabetes.
Am J Physiol Renal Physiol
. 2010 Jan; 298(1):F37–48.7.
Kamiyama M, Zsombok A, Kobori H. Urinary angiotensinogen as a novel early biomarker of intrarenal renin-angiotensin system activation in experimental type 1 diabetes.
J Pharmacol Sci
. 2012; 119(4): 314–23.8.
Hsieh TJ, Fustier P, Wei CC, Zhang SL, Filep JG, Tang SS, et al. Reactive oxygen species blockade and action of insulin on expression of angiotensinogen gene in proximal tubular cells.
J Endocrinol
. 2004 Dec; 183(3): 535–50.9.
List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.
Diabetes Care
. 2009 Apr; 32(4): 650–7.10.
Foote C, Perkovic V, Neal B. Effects of SGLT2 inhibitors on cardiovascular outcomes.
Diab Vasc Dis Res
. 2012 Apr; 9(2): 117–23.11.
Weber MA, Mansfield TA, Cain VA, Iqbal N, Parikh S, Ptaszynska A. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study.
Lancet Diabetes Endocrinol
. 2016 Mar; 4(3): 211–20.12.
Yale JF, Bakris G, Cariou B, Yue D, David-Neto E, Xi L, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease.
Diabetes Obes Metab
. 2013 May; 15(5): 463–73.13.
Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al.; CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
N Engl J Med
. 2017 Aug; 377(7): 644–57.14.
Bielschowsky F, Bielschowsky M. The New Zealand strain of obese mice; their response to stilboestrol and to insulin.
Aust J Exp Biol Med Sci
. 1956 Jun; 34(3): 181–98.15.
Mirhashemi F, Scherneck S, Kluth O, Kaiser D, Vogel H, Kluge R, et al. Diet dependence of diabetes in the New Zealand Obese (NZO) mouse: total fat, but not fat quality or sucrose accelerates and aggravates diabetes.
Exp Clin Endocrinol Diabetes
. 2011 Mar; 119(3): 167–71.16.
Liu J, Edgington-Giordano F, Dugas C, Abrams A, Katakam P, Satou R, et al. Regulation of Nephron Progenitor Cell Self-Renewal by Intermediary Metabolism.
J Am Soc Nephrol
. 2017 Nov; 28(11): 3323–35.17.
O’Leary R, Penrose H, Miyata K, Satou R. Macrophage-derived IL-6 contributes to ANG II-mediated angiotensinogen stimulation in renal proximal tubular cells.
Am J Physiol Renal Physiol
. 2016 May; 310(10):F1000–7.18.
Satou R, Kobori H, Katsurada A, Miyata K, Navar LG. Quantification of intact plasma AGT consisting of oxidized and reduced conformations using a modified ELISA.
Am J Physiol Renal Physiol
. 2016 Dec; 311(6):F1211–6.19.
Tsukahara C, Sugiyama F, Paigen B, Kunita S, Yagami K. Blood pressure in 15 inbred mouse strains and its lack of relation with obesity and insulin resistance in the progeny of an NZO/HILtJ x C3H/HeJ intercross.
Mamm Genome
. 2004 Dec; 15(12): 943–50.20.
Brasier AR, Li J. Mechanisms for inducible control of angiotensinogen gene transcription.
Hypertension
. 1996 Mar; 27(3 Pt 2): 465–75.21.
Pahlavani M, Kalupahana NS, Ramalingam L, Moustaid-Moussa N. Regulation and Functions of the Renin-Angiotensin System in White and Brown Adipose Tissue.
Compr Physiol
. 2017 Sep; 7(4): 1137–50.22.
Yiannikouris F, Gupte M, Putnam K, Thatcher S, Charnigo R, Rateri DL, et al. Adipocyte deficiency of angiotensinogen prevents obesity-induced hypertension in male mice.
Hypertension
. 2012 Dec; 60(6): 1524–30.23.
van Bommel EJ, Muskiet MH, Tonneijck L, Kramer MH, Nieuwdorp M, van Raalte DH. SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome.
Clin J Am Soc Nephrol
. 2017 Apr; 12(4): 700–10.24.
Cefalu WT, Stenlöf K, Leiter LA, Wilding JP, Blonde L, Polidori D, et al. Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes.
Diabetologia
. 2015 Jun; 58(6): 1183–7.25.
Shin SJ, Chung S, Kim SJ, Lee EM, Yoo YH, Kim JW, et al. Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes.
PLoS One
. 2016 Nov; 11(11):e0165703.26.
Han E, Shin E, Kim G, Lee JY, Lee YH, Lee BW, et al. Combining SGLT2 Inhibition With a Thiazolidinedione Additively Attenuate the Very Early Phase of Diabetic Nephropathy Progression in Type 2 Diabetes Mellitus.
Front Endocrinol (Lausanne)
. 2018 Jul; 9: 412.27.
Yoshimoto T, Furuki T, Kobori H, Miyakawa M, Imachi H, Murao K, Nishiyama A. Effects of sodium-glucose cotransporter 2 inhibitors on urinary excretion of intact and total angiotensinogen in patients with type 2 diabetes.
J Investig Med
. 2017 Oct; 65(7): 1057–1061.28.
Wang XX, Levi J, Luo Y, Myakala K, Herman-Edelstein M, Qiu L, et al. SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy: SGLT2 PROTEIN INHIBITION DECREASES RENAL LIPID ACCUMULATION, INFLAMMATION, AND THE DEVELOPMENT OF NEPHROPATHY IN DIABETIC MICE.
J Biol Chem
. 2017 Mar; 292(13): 5335–48.29.
Takeshige Y, Fujisawa Y, Rahman A, Kittikulsuth W, Nakano D, Mori H, et al. A sodium-glucose co-transporter 2 inhibitor empagliflozin prevents abnormality of circadian rhythm of blood pressure in salt-treated obese rats.
Hypertens Res
. 2016 Jun; 39(6): 415–22.30.
Gallo LA, Ward MS, Fotheringham AK, Zhuang A, Borg DJ, Flemming NB, et al. Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice.
Sci Rep
. 2016 May; 6(1): 26428.31.
Vallon V, Gerasimova M, Rose MA, Masuda T, Satriano J, Mayoux E, et al. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice.
Am J Physiol Renal Physiol
. 2014 Jan; 306(2):F194–204.32.
Terami N, Ogawa D, Tachibana H, Hatanaka T, Wada J, Nakatsuka A, et al. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice.
PLoS One
. 2014 Jun; 9(6):e100777.33.
Kojima N, Williams JM, Slaughter TN, Kato S, Takahashi T, Miyata N, et al. Renoprotective effects of combined SGLT2 and ACE inhibitor therapy in diabetic Dahl S rats.
Physiol Rep
. 2015 Jul; 3(7):e12436.34.
Mancia G, Cannon CP, Tikkanen I, Zeller C, Ley L, Woerle HJ, et al. Impact of Empagliflozin on Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension by Background Antihypertensive Medication.
Hypertension
. 2016 Dec; 68(6): 1355–64.35.
Kario K, Okada K, Kato M, Nishizawa M, Yoshida T, Asano T, et al. 24-Hour Blood Pressure-Lowering Effect of an SGLT-2 Inhibitor in Patients with Diabetes and Uncontrolled Nocturnal Hypertension: Results from the Randomized, Placebo-Controlled SACRA Study.
Circulation
. 2018 Nov 29.
